Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS

Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS

Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
RestartResume
    European Commission Grants Approval for Mavenclad (Cladribine Tablets)
    • Overview

      The European Commission (EC) has granted authorization of MAVENCLAD® 10mg (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis* (RMS)[1] in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity.

      To learn more about current and future treatment options for MS patients, click here. 

    Facebook Comments

    Sign-up for the Global Neurology Academy newsletters.
    Comprehensive Neurology Education.

    Better education for a better you.

    * Required
    Optional
    Register

    Join the Global Neurology Academy of learners.
    Registration is free and easy.

    Register Now